Migoprotafib
Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity[1][2].
Product Specifications
CAS Number
[2377352-49-1]
Product Name Alternative
GDC-1971
UNSPSC
12352005
Target
ERK; p38 MAPK; Phosphatase; SHP2
Type
Reference compound
Related Pathways
MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/r-gdc-1971.html
Purity
98.81
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
N[C@H]1C2(CCN(C3=CN=C(C(N4C5=CC=CN=C5CCC4)=NN6)C6=N3)CC2)OC7=CC=CC=C71
Molecular Formula
C25H26N8O
Molecular Weight
454.53
References & Citations
[1]Alexander M, et al. Shp2 phosphatase inhibitors and methods of use thereof. Patent WO2019183367A1.|[2]Maddalo D, et al. RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy[J]. 2024.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
